Feline calicivirus VP1-based mRNA vaccine protects cats against FCV challenge

Figures

• 

  Fig. 1. Feline calicivirus VP1-based mRNA vaccine protects cats against FCV challenge. A Identification of mRNA vaccines encoding FCV-VP1 by IFA and WB in vitro. B Experimental design for evaluation of the immune efficacy in cats. C Neutralizing antibody levels after immunization. D The body weight gain rate of cats during the immunization period. E, F: Change Variations in body temperature and weight after challenge. G The clinical signs were monitored daily and scored of cats following challenge. H: The blood viral load was measured via RT‒qPCR (a 135 bp conserved region spanning the P76-VP1 junction). I: Kinetics of FCV Neutralizing antibody titers from week 0 to week 48. Statistical analyses were conducted using one-way ANOVA (F) or two-way ANOVA (C, G and F) followed by Tukey's multiple comparisons test. Different lowercase letters (a, b, c, d) above the bars indicate statistically significant differences between groups (P < 0.05), while groups sharing the same letter are not significantly different.